UNASSIGNED: The purpose of this study was to analyze the dosimetry and investigate the clinical outcomes of radiation-induced @entity174 (RIRFs) after stereotactic body radiotherapy (SBRT). A total of 126 @entity1 with Stage I primary @entity2 treated with SBRT, who had undergone follow-up computed tomography (CT) at least 12 months after SBRT and who had no previous overlapping radiation exposure were included in the study. We used the Mantel-Haenszel method and multiple logistic regression analysis to compare risk factors. We analyzed D(0.5 cm(3)) (minimum absolute dose received by a 0.5-cm(3) volume) and identified each rib that received a biologically effective dose (BED) (BED3, using the linear-quadratic (LQ) formulation assuming an a/b = 3) of at least 50 Gy. Of the 126 @entity1 , 46 (37%) suffered a total of 77 RIRFs. The median interval from SBRT to RIRF detection was 15 months (range, 3-56 months). The 3-year cumulative probabilities were 45% (95% CI, 34-56%) and 3% (95% CI, 0-6%), for Grades 1 and 2 RIRFs, respectively. Multivariate analysis showed that @entity5 location was a statistically significant risk factor for the development of Grade 1 RIRFs. Of the 77 RIRFs, 71 (92%) developed in the true ribs (ribs 1-7), and the remaining six developed in the false ribs (ribs 8-12). The BED3 associated with 10% and 50% probabilities of RIRF were 55 and 210 Gy to the true ribs and 240 and 260 Gy to the false ribs. We conclude that RIRFs develop more frequently in true ribs than in false ribs.

Differences in rates of radiation-induced true and false XXXX after stereotactic body radiation therapy for Stage I primary @entity2 .

@entity1 :: ('9606', 'Species') :: ['patients'] @entity2 :: ('MESH:D008175', 'Disease') :: ['lung cancer'] @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor'] @entity174 :: ('MESH:D050723', 'Disease') :: ['rib fractures']
@entity174 :: (MESH:D050723,Disease) :: ['rib fractures']
